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Abstract
Background: Despite being expensive, the standard combination of pegylated interferon (Peg-IFN)- a and ribavirin used to
treat chronic hepatitis C (CH) results in a moderate clearance rate and a plethora of side effects. This makes it necessary to
predict patient outcome so as to improve the accuracy of treatment. Although the antiviral mechanism of genetically
altered IL28B is unknown, IL28B polymorphism is considered a good predictor of IFN combination treatment outcome.
Methodology: Using microarray, we quantified the expression profile of 237 IFN related genes in 87 CH liver biopsy
specimens to clarify the relationship between IFN pathway and viral elimination, and to predict patients’ clinical outcome. In
72 out of 87 patients we also analyzed IL28B polymorphism (rs8099917).
Principal Findings: Five IFN related-genes (IFI27, IFI 44, ISG15, MX1, and OAS1) had expression levels significantly higher in
nonresponders (NR) than in normal liver (NL) and sustained virological responders (SVR); this high expression was also
frequently seen in cases with the minor (TG or GG) IL28B genotype. The expression pattern of 31 IFN related-genes also
differed significantly between NR and NL. We predicted drug response in NR with 86.1% accuracy by diagonal linear
discriminant analysis (DLDA).
Conclusion: IFN system dysregulation before treatment was associated with poor IFN therapy response. Determining IFN
related-gene expression pattern based on patients’ response to combination therapy, allowed us to predict drug response
with high accuracy. This method can be applied to establishing novel antiviral therapies and strategies for patients using a
more individual approach.
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Introduction
Hepatitis C virus (HCV) infection affects more than 3% of the
world population. Without suitable treatment, chronic hepatitis C
(CH) frequently leads to the development of chronic liver diseases
such as liver cirrhosis (LC) and hepatocellular carcinoma (HCC)
[1]. The current standard treatment for CH is a combination of
pegylated-IFN (Peg-IFN)- a and ribavirin (hereafter CH combi-
nation therapy). Over a 15-year observation period, the rate of
hepatocarcinogenesis was found to be significantly lower in
sustained viral responders (SVR) and relapse (R) patients than in
non responders (NR) and interferon (IFN) untreated patients [2].
However, CH combination therapy achieves a sustained virolog-
ical response in 50–55% of patients with HCV genotype 1b
infection [3]. Consequently, this creates a pressing need to develop
alternative strategies for treating CH.
IFN Type-I and III play various important immunomodulatory
roles in both innate immune and acquired immune responses.
Four main effector pathways of the IFN-mediated antiviral
response have been recognized by gene targeting studies: the
Mx GTPase pathway, the 29,5 9-oligoadenylate-synthetase-direct-
ed ribonuclease L (OASL) pathway, the protein kinase R (PKR)
pathway and the interferon stimulated gene (ISG) 15 ubiquitin-
like pathway. These effector-pathways individually block viral
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19799transcription, degrade viral RNA, inhibit translation and modify
protein function to control all steps of viral replication [4–5].
IFN treatment for CH usually results in a high incidence of side
effects; therefore, it is important to adjust IFN treatment
accurately using a prediction method. Viral factors (HCV
genotype, pretreatment viral load, and sequence of HCV gene
core and NS5A), [6–7] host factors (obesity, cirrhosis, ethnic
background, serum cytokine levels, liver fibrosis grades) [8], and
treatment factors (adequate course of treatment, adherence to the
treatment, management of side effects) [9] has been utilized in
prior research to predict the outcome of combination therapy.
Hepatic microRNA expression pattern before anti-viral treatment
has also been utilized as a prediction biomarker of drug response
in CH [10], while other studies have shown that there is a possible
association between two SNPs near the gene interleukin 28B
(IL28B) on chromosome 19 and lack of response to combination
therapy [11–13].
In this study, we evaluated the IFN related gene expression
profiles in CH patients before administering CH combination
treatment. After the anti-viral therapy, patients were classified
according to their clinical outcome: sustained viral response
(SVR), relapse (R), and non responder (NR). It was observed that
in the NR group, the expression level of some IFN related genes
was significantly higher than that in normal liver (NL) groups, and
that the expression level of the other IFN related genes was
significantly lower than in NL. Moreover, the significantly high
expression of IFN related genes was associated with low response
to combination therapy. This suggests that dysregulation of the
IFN system can be related to cases of CH combination therapy
failure.
Results
In order to provide specific information with less data analysis,
we developed a custom-made focused DNA microarray called
Genopal (Mitsubishi Rayon, Tokyo, Japan) using genes that target
human innate-immunity. Based on the results from the expression
profiles, we carefully selected 237 gene probes (materials and
methods) by activating RIG-I with Agilent DNA microarray. A
microarray platform was used to establish IFN-related gene
expression profiles in the specimens collected from the 87 CH and
5 NL samples (Table 1). The results of the analysis of these genes
using the DNA chip strongly correlated with those obtained by
real-time PCR (Pearson’s correlation coefficient R2=0.996,
P,0.0001; data not shown).
IFN related genes associated with the final response to
combination therapy
We determined unique IFN gene expression patterns for liver
specimens with or without HCV based on the final virological
response to the combination therapy. The expression level of 66
genes significantly differed among NR, R, SVR, and normal liver
(NL) groups (Figure 1). To clearly identify the IFN-related genes
associated with the clinical outcome, we extracted genes that
showed significant differences (p,0.05). It was observed that the
expression level of 5 genes (myxovirus (influenza virus) resistance 1
(MX1), 20,50-oligoadenylate synthetase 1 (OAS1), ISG15 ubiqui-
tin-like modifier (ISG15), interferon, alpha-inducible protein 27
(IFI27), and interferon, alpha-inducible protein 44 (IFI44)) were
significantly higher in NR than in SVR samples (Table 2). The
expression levels of 3 genes (MX1, IFI27, and ISG15) were
significantly higher in NR than in R samples (Table 2). We also
analyzed the IFN-related genes expression pattern according to
the grade of inflammation or stage of fibrosis, however, no
significant differences was observed between the two (data not
shown).
Comparison of IFN related genes between CH and NL
We also compared the gene expression pattern in NR and NL.
After extracting genes with a fold change ,1/3, 3, and p-
value,0.05, we found that the expression level of 6 genes (growth
arrest and DNA-damage-inducible, beta (GADD45B), hairy and
enhancer of split 1 (HES1), B-cell CLL/lymphoma 3 (BCL3),
signal transducer and activator of transcription 3 (STAT3),
suppressor of cytokine signaling 3 (SOCS3), and DEAD/H (Asp-
Glu-Ala-Asp/His) box polypeptide 11 (DDX11)) was significantly
lower in NR than in NL. The expression level of SOCS3 and
DDX11 in NR was significantly lower than in SVR. The
expression level of 25 genes were significantly higher in NR than
in NL. The expression levels of most of these genes were
significantly higher in NR than in SVR, but the expression level of
tumor necrosis factor (ligand) superfamily, member 10 (TRAIL),
major histocompatibility complex, class I, C (HLA–C), major
histocompatibility complex, class I, B (HLA–B), and chemokine
(C-X-C motif) ligand 10 (CXCL10 (IP10)) were similar in NR and
SVR samples (Table 3).
Validation of the microarray result by real-time qPCR
The five genes (ISG15, MX1, OAS1, IFI27 and IFI44) with the
largest difference in fold change between NR and SVR groups
were chosen to confirm the microarray results using real-time
Table 1. Clinical characteristics of patients.
Characteristics SVR (n=38) R (n=26) NR (n=23) NL (n=5)
Age 56.7610.3 61.368.6 60.867.8 57.269.5
Male (%) 28 (61%) 11 (39%) 9 (36%) 3(60%)
Weight (kg) 59.568.9 57.2610.3 55.767.2 ND
HCV RNA
(x10
6 copies/ml)
2.0062.07 1.7961.02 1.5560.95 ND
Fibrosis stage
F0 1 1 1
F 1 29 13 10
F2 9 7 5
F3 6 4 6
F4 0 0 1
WBC(610
3/mm
3) 5.4261.63 5.2361.25 4.6961.13 ND
Hemoglobin (g/dl) 14.361.14 13.561.35 13.661.09 ND
Platelet
(610
4/mm
3)
16.765.3 16.664.0 15.065.7 ND
AST (IU/L) 59.2651.0 48.7630.1 57.4629.7 ND
ALT (IU/L) 80.8693.7 49.3629.6 69.1644.4 ND
cGTP (IU/L) 60.3674.2 41.2629.7 76.2660.2 ND
ALP (IU/L) 255674.0 246671.3 3146144 ND
Total bilirubin
(mg/dl)
0.6660.22 0.7360.31 0.6960.19 ND
Albumin (g/dl) 4.2060.34 4.1460.25 4.0260.48 ND
Abbreviations; NR, non-virological responder; R, relapse; SVR, sustained
virological responder; AST, aspartate aminotransferase;ALT, alanine
aminotransferase; WBC, white blood cell; ALP, alkaline phosphatase; cGTP,
gamma-glutamyl transpeptidase; ND, not detected.
doi:10.1371/journal.pone.0019799.t001
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the microarray analysis (Figure S1).
Prediction of the clinical outcome by DLDA
We attempted to simulate the clinical outcome of the CH
combination therapy using diagonal linear discriminant analysis
(DLDA). Patients were randomly divided into TS (training set) and
VS (validation set) (Table 4) in the order in which their samples
were obtained. Samples within each group were then classified as
NR or non-NR (SVR+R). DLDA showed that the accuracy,
sensitivity, specificity, positive and negative predictive value of
these two classifications were 86.1%, 87.5%, 81.8%, 93.3%, and
Figure 1. Clustering of IFN related gene expression. Clustering of CH patients according to the expression profiles of the 66 genes that
showed significant differences among SVR, R, NR, and NL. Vertical bars represent the IFN related genes and the horizontal bars represent the samples.
Green bars reflect down-regulated genes and red bars up-regulated genes.
doi:10.1371/journal.pone.0019799.g001
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predict (1) SVR and nonSVR (R+NR), and (2) SVR, R, and NR
by DLDA. The accuracy with which patients were classified as
SVR and nonSVR, was 56.8% and as SVR, R, and NR was
56.9%.
Genetic variation of IL28B is correlated with the
expression of IFN related genes
To examine the relationship between the genetic variation of
IL28B and IFN related gene expression, we determined the IL28B
polymorphism in 72 patients (Table 6). Patients with the minor
genotype of IL28B displayed higher levels of hepatic ISGs
expression, whereas patients with the major genotype showed
significantly lower expression levels (Figure 2A). In order to further
widen our understanding of the above relationship, we signifi-
cantly identified individual genetic variations in IL28B at the
clinical outcome (Figure 2B). We then individually compared the
expression level of several IFN-lambda related genes at the clinical
outcome with the genetic variation of IL28B. The expression level
of interleukin 28A (IL28A), IL28B, interleukin 29 (IL29),
interleukin 10 receptor, beta (IL10RB), signal transducer and
activator of transcription 1 (STAT1), STAT5A, and tyrosine
kinase 2 (TYK2) in IL28B genotype minor allele and major allele
did not differ; however, the expression level of STAT5A and IRF9
was significantly higher in IL28B minor allele cases than in major
allele (Figure 3A). The expression levels of these nine genes did not
significantly differ among the clinical outcomes (NR, R, and SVR)
(Figure 3B).
Finally, in regards to genes which contribute to IFN production
(interferon regulatory factor 7 (IRF7), interleukin-1 receptor-
associated kinase 1 (IRAK1), myeloid differentiation primary
response gene (MyD88), and toll-like receptor 7 (TLR7)) there was
not much difference in their expression level prior to CH
combination treatment and their expression level at the clinical
outcome (Figure 4A) [14]. Unlike IRF7 and MyD88, there was no
significant difference in the expression level of IRAK1 and TLR7
according to the IL28B genetic variation (Figure 4B). When we
attempted to predict NR and nonNR by using ISG genes with and
without IL28B polymorphism using DLDA by using 72 patients
(36 patients for training set, 36 patients for validation set). DLDA
with IFN related gene and IL28B polymorphism showed that the
accuracy, sensitivity, specificity, positive and negative predictive
value of these two classifications were 83.3%, 85.1%, 77.8%,
92.0%, 63.6%, respectively (Table 7). DLDA with IFN related
gene only showed that the accuracy, sensitivity, specificity, positive
and negative predictive value were 83.3%, 81.5%, 88.9%, 95.7%,
61.5%, respectively (Table 8).
Discussion
Our comprehensive analysis identified 66 genes with expression
levels that consistently differed depending on the drug response of
87 CH patients and 5 normal liver specimens (Figure 1).
Comparing the gene expression pattern in NR and NL showed
the expression levels of 31 genes were significantly different
(Table 3). In addition, most genes with expression levels in NR
that were higher or lower than in NL, also differed between NR
and SVR. Therefore, it is possible that innate immunity in the
early period of HCV infection strongly influences IFN reaction.
HCV infection induces the impairment of cell subset number
and the function of plasmacytoid dendritic cells (PDC) and natural
killer cells [15]. The amount of PDC, which are the most potent
producers of antiviral Type-I and III IFN [16], decreased in
patients’ peripheral blood [17], however, PDC was trapped in the
HCV infected liver tissue. Therapeutic non-responders had
increased PDC migration to inflammatory chemokines before
therapy, compared with therapeutic responders [18]. This
situation resulted in elevated expressions of IFN-related genes in
the CH samples and was associated with their inability to eliminate
the virus [19].
Inadequate expression of IFN related genes has been associated
with several diseases. High expression of ISG can induce a
refractory state in IFN therapy [20] and impaired IFN production
leads to high risk of HCV-related hepatocarcinogenesis [21].
Lymphocyte IFN signaling was less responsive in patients with
breast cancer, melanoma, and gastrointestinal cancer and these
defects may represent a common cancer-associated mechanism of
immune dysfunction. Alternately, since immunotherapeutic strat-
egies require functional immune activation, such impaired IFN
signaling may hinder therapeutic approaches designed to stimulate
anti-tumor immunity [22]. In this way, the dysregulation of the
IFN system can influence the progression of diseases and decrease
curative effects.
Table 2. Extracted genes related to the clinical outcome with a fold change greater than or equal to 1.5 between two groups (NR/
SVR, NR/R) (p,0.05).
Accession No. gene symbol fold change (NR/SVR) p-value
NM_006417.4 interferon, alpha-inducible protein 44 IFI44 2.13 2.01E-03
NM_005532.3 interferon, alpha-inducible protein 27 IFI27* 2.37 2.01E-03
NM_016816.2 20,50-oligoadenylate synthetase 1, 40/46kDa,
transcript variant 1
OAS1 2.51 1.36E-02
NM_005101.2 ISG15 ubiquitin-like modifier ISG15* 2.68 1.18E-03
NM_002462.2 myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
MX1* 2.71 1.57E-03
Accession No. gene symbol fold change (NR/R) p-value
NM_002462.2 myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
MX1* 2.27 1.11E-03
NM_005532.3 interferon, alpha-inducible protein 27 IFI27* 2.33 1.69E-03
NM_005101.2 ISG15 ubiquitin-like modifier ISG15* 2.5 1.11E-03
Asterisk deposits extracted genes that are common to both SVR and NR and to NR and R.
doi:10.1371/journal.pone.0019799.t002
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IRAK1, and IRF7) did not show any significant difference in their
expression level prior to CH combination therapy, and their level
at the clinical outcome (Figure 4A and 4B). However, the gene
expression pattern of down-stream IFN pathway genes (IFI27,
IFI44, ISG15, MX1, and OAS1) was significantly different among
SVR, R, and NR (Table 2). IFN is usually up-regulated in HCV
infected cells; however in some cases, the mechanism that controls
IFN becomes abnormal, and the expression levels of IFN and ISG
remain high without any curative effect [23]. The ISG family was
generally up-regulated in NR compared to SVR [24–27] and this
high expression of ISG related genes was associated with poor
response to IFN therapy in previous, as well as in this present
study. ISG15 has been linked to innate immune response to viruses
and to cellular response to IFN. Although over-expression of
ISG15 enhances the antiviral activity of IFN in vitro in acute
infection [28], in chronic infection, extended pre-activation of IFN
induced genes leads to dysregulation of the IFN system.
CH therapy is still imperfect at present and therefore suitable
prediction methods are necessary to avoid adverse effects.
Treatment failure using CH combination therapy is associated
with up-regulation of a specific set of IFN-responsive genes thereby
making it possible to predict non-response to exogenous therapy
[29]. Early gene expression during anti-HCV therapy may
elucidate important molecular pathways that might be influencing
the probability of achieving a virological response [30]. Our study
supports this fact by demonstrating that CH and NL differ
fundamentally in their innate response to CH combination
therapy.
IFN related gene expression suggests novel aspects of HCV
pathogenesis, and form the basis for a subset of genes that can
predict treatment response before initiation of combination
therapy. After proper external validation, these gene sets may
provide the basis for a diagnostic biomarker that can determine
early on whether a patient treated with combination therapy is
likely to be NR or not. In this respect, what sets our analysis apart
is the effect of using DLDA to predict final response with high
accuracy in NR and non-NR groups. This prediction showed that
the expectation in NR (proportion of actual non-NR versus the
predicted number of non-NR) was 93.3% and overall accuracy
was 86.1%. In prior report, Dill et al. successfully predicted SVR,
but were unable to predict R and NR with high accuracy [31]. In
our experiments on the other hand, we predicted NR with high
accuracy but were unable to do so for SVR and R. Possible causes
for differences between our results and those received by Dill et al.
may be (1) the differences in the races of subjects; European
patients vs. Japanese patients in our study, (2) the composition of
genotype; genotype 1 and 4 vs. genotype 1b in our study, and (3)
the difference of the ISG genes extracted.
Genome-wide association studies have described alleic variants
near the IL28B gene that are associated with treatment response
and with spontaneous clearance of HCV [11–13]. In order to
clarify the relationship between IL28B polymorphism and drug
response, we compared the expression level of IFN-lambda related
gene at the clinical outcome with any genetic variation in IL28B.
The expression of hepatic ISG and related genes was strongly
associated with treatment response and genetic variation of IL28B
[32]. Classification of the patients into SVR and NR revealed that
ISG expression was conditionally independent of the IL28B
genotype. In CH patients in Europe, the expression pattern of
genes induced by IFN more accurately predicts CH combination
treatment clinical outcome than polymorphism of IL28B [31]. We
observed that curative effect prediction using IFN gene expression
pattern resulted in high level of accuracy, however, IFN with
IL28B or IFN alone resulted in approximately similar levels of
accuracy, therefore, the polymorphism of IL28B did not
contribute significantly to our prediction. These findings are
accordance with Dill et al. results (Table 7). There was an
increased expression in NR compared to SVR irrespective of the
IL28B genotype. However, there was no significant difference in
their expression at the clinical outcome or in the genetic variation
of IL28B (Figure 3A and 3B). Genetic variation of IL28B
polymorphism is effective in predicting curative effect; however,
the reason for this is not fully understood.
In conclusion, comprehensive analysis of IFN related gene
showed that dysregulation of the IFN system might be related to
treatment failure and that IFN related gene expression before
treatment can enable accurate prediction of CH combination
therapy clinical outcome. By focusing the full course of treatment
on only those patients who have the highest likelihood of achieving
Table 3. List of genes that had significantly different
expression levels in NR and NL (fold change ,1/3, 3,, and
p,0.05).
symbol
NR/NL
(fold
change)
NR/NL
(t-test)
NR/SVR
(fold
change)
NR/SVR
(t-test)
GADD45B 0.20 1.14E-02 1.01 NS
HES1 0.26 1.26E-03 0.97 NS
BCL3 0.26 1.84E-02 1.02 NS
STAT3 0.26 5.81E-04 0.97 NS
SOCS3 0.27 7.96E-03 0.68 2.15E-02
DDX11 0.28 4.33E-05 0.59 9.52E-03
TRIM22 3.06 2.91E-03 1.37 7.97E-03
ASC 3.19 1.35E-03 1.33 4.07E-03
UBE2L6 3.32 1.06E-02 1.41 1.01E-03
STAT1 3.38 6.04E-04 1.33 1.86E-02
ISG20 3.64 2.42E-04 1.42 2.37E-03
TRAIL 3.81 2.08E-02 0.78 NS
OAS2 4.02 2.91E-03 1.89 1.07E-04
IFIT2 4.60 1.48E-03 1.56 8.34E-05
BST2(Tetherin) 5.14 8.17E-03 1.49 5.67E-04
IFI35 5.29 1.35E-03 1.63 2.37E-05
HERC5 5.32 1.16E-03 1.68 4.07E-05
MX1 6.21 1.33E-03 2.94 8.46E-07
HLA-C 6.49 6.34E-04 1.21 NS
CCL5(RANTES) 6.73 5.48E-04 1.25 3.77E-02
HLA-B 6.84 4.91E-04 1.22 NS
OAS1 7.80 5.52E-04 2.75 1.92E-04
HLA-A 8.49 5.92E-05 1.41 9.08E-04
B2m 9.09 7.78E-04 1.25 1.89E-02
IFIT1 9.42 1.86E-03 2.11 1.41E-05
OASL 10.38 3.97E-06 1.48 1.24E-02
IFIT3 10.45 4.33E-05 2.11 5.63E-06
CXCL10(IP10) 15.67 8.89E-07 1.28 NS
IFI44 17.00 9.40E-05 2.22 4.83E-06
ISG15 21.12 1.05E-04 2.85 3.99E-05
IFI27 43.74 1.80E-05 2.56 5.62E-05
doi:10.1371/journal.pone.0019799.t003
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associated with these regimens and provide a more personalized
approach to treating CH patients.
Materials and Methods
Patients and sample preparation
Eighty seven CH patients with HCV genotype 1b in the
Department of Gastroenterology at the Ogaki Municipal Hospital
were enrolled between 2004 and 2006 (Table 1). Patients with
autoimmune hepatitis, alcohol-induced liver injury, and patients
positive for hepatitis B virus associated antigen/antibody or anti-
human immunodeficiency virus antibody were excluded. None of
the patients had received IFN therapy or immunomodulatory
therapy prior to enrollment. Five normal liver specimens were
obtained by surgical resection. Three of these were obtained from
Osaka City University Hospital and were taken from gall bladder
cancer, cholangiocarcinoma, and hemangioma patients whose
liver tissue were normal based on histological, virological and
blood examination of their liver function. The remaining two
normal liver samples were obtained from the Liver Transplanta-
tion Unit of Kyoto University Hospital.
Patients’ serum HCV RNA was quantified before IFN
treatment using Amplicor-HCV Monitor Assay (Roche Molecular
Diagnostics Co., Tokyo, Japan). Histological grading and staging
of liver biopsy specimens from the CH patients were performed
according to the Metavir classification system. Pretreatment blood
samples were analyzed to determine the level of aspartate
aminotransferase, alanine aminotransferase (ALT), total bilirubin,
alkaline phosphatase (ALP), gamma-glutamyl transpeptidase
(cGTP), white blood cell (WBC), platelets, and hemoglobin.
Written informed consent was obtained from all patients or their
guardians and provided to the Ethics Committee of the Graduate
School of Kyoto University, Osaka City University and Ogaki
Municipal Hospital, who approved this study in accordance with
the Helsinki Declaration.
Treatment protocol
For all enrolled patients, treatment with PegIFN- a-2b
(Schering-Plough Corporation, Kenilworth, NJ, USA) and ribavi-
rin (Schering-Plough) was initiated at the beginning of the 1st week
and lasted for 48 weeks. PegIFN was administrated at a dose of
1.5 mg kg/week and ribavirin was administrated at the dose
recommended by the manufacturer.
Definition of drug response to therapy
The patients were classified into the following three groups at
the completion of follow-up period (24 weeks): (1) sustained
virological responder (SVR): a patient who was negative for serum
HCV RNA during the 24 weeks following the completion of the
Table 4. Characteristics of the training and validation set.
non NR (SVR+R)
group
non NR (SVR+R)
group NR group NR group
average
(training set)
average
(validation set) p-value
average
(training set)
average
(validation set) p-value
No. 32 32 12 11
Age 59.3 57.1 0.38 60.6 61.7 0.74
HCVRNA (610
6 IU/ml) 1.77 2.08 0.48 1.51 1.52 0.97
AST (IU/L) 44.6 65.3 0.06 55.3 56.9 0.89
ALT (IU/L) 50 87.3 0.05 67.7 66.8 0.96
WBC(610
3/mm
3) 5220 5440 0.57 4610 4860 0.6
Platelet (610
4/mm
3) 15.8 17.6 0.15 15 15.2 0.95
Total bilirubin (mg/dl) 0.71 0.69 0.78 0.68 0.68 0.92
weight 58.1 59.2 0.67 57 53.8 0.28
ALP (IU/L) 251 249 0.92 298 326 0.64
gGTP (IU/L) 48 57.4 0.54 73.3 73.8 0.98
Hemoglobin (g/dl) 13.9 14.1 0.53 13.7 13.5 0.78
Albumin (g/dl) 4.15 4.21 0.41 4.11 3.98 0.52
doi:10.1371/journal.pone.0019799.t004
Table 5. Quality of NR-prediction by DLDA.
Predicted
NR nonNR(SVR+R) Total
Diagnosed NR 9 2 11
nonNR(SVR+R) 4 28 32
Total 13 30 43
doi:10.1371/journal.pone.0019799.t005
Table 6. Result of the IL28B polymorphism (rs8099917).
rs8099917
TT TG GG
outcome NR 7 12 1
Relapse 18 3 0
SVR 30 1 0
Total 55 16 1
doi:10.1371/journal.pone.0019799.t006
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19799Figure 2. The relationship among the expression of IFN-related genes, IL28B polymorphism and clinical outcome. (A) The relationship
between expression of ISG and five related genes (MX1, OAS1, ISG15, IFI27, and IFI44) in the liver of CH patients and IL28B with the major (TT) or
minor (TG or GG) genotype (rs8099917) is shown. The p-value of the relationship between gene expression level and IL28B genotype is also depicted.
(B) The relationship among the expression level of the above five genes, clinical outcome, and IL28 genotype in individual cases. Red square, green
circle, and blue rectangle represent TT, TG, and GG in IL28B genotype, respectively. The p value was calculated from a linear regression employing
outcome as an explanatory variable (in which SVR, R and NR are encoded to 0, 1 and 2 respectively) and expression level as the response variable. We
tested the null hypothesis that the coefficient of the outcome is 0. Summary table of the p-value is also shown. NS shows no significant difference.
doi:10.1371/journal.pone.0019799.g002
Figure 3. The relationship among the expression of IFN lambda-related genes, IL28B polymorphism and clinical outcome. (A) The
relationship between the expression level of IFN lambda related genes (TYK2, STAT5A, STAT1, IL10RB, IL29, IL28A, IL28B, JAK1, and IRF9) in the liver of
CH patients and IL28B with genotype. The p-value of the relationship between gene expression level and IL28B genotype is also presented. (B) The
relationship among IFN lambda related genes, clinical outcome, and IL28 genotype in individual cases. Summary table of the p-value is also shown.
NS was not significantly different.
doi:10.1371/journal.pone.0019799.g003
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RNA was negative by the end of the combination therapy but
reappeared during the 24 week observation period; and (3) non
responder (NR): a patient who was positive for serum HCV RNA
during the entire course of the combination therapy (Figure 5). No
patients were withdrawn from the study due to side effects or any
other reason.
RNA preparation and real-time qPCR
Total RNA from tissue samples was prepared using a
mirVana miRNA extraction Kit (Ambion, Austin, TX, USA)
according to the manufacturer’s instruction. cDNA was
synthesized by Transcriptor High Fidelity cDNA synthesis Kit
(Roche, Basel, Switzerland). Total RNA (2 mg) in 11 mlo f
nuclease free water was added to 1 mlo f5 0 mMr a n d o m
hexamer and denatured for 10 min at 65uC. The denatured
RNA mixture was added to 4 ml of 5x reverse transcri-
ptase buffer, 2 mlo f1 0m Md N T P ,0 . 5mlo f4 0U / m lR N a s e
inhibitor, and 0.5 ml of reverse transcriptase (FastStart Universal
SYBR Green Master (Roche) in a total volume of 20 ml. cDNA
synthesis was performed for 30 min at 50uC, and enzyme
denaturation for 5 min at 85uC. Chromo 4 detector (Bio-Rad,
Hercules, CA, USA) was used to detect mRNA expression.
Assays were performed in triplicate, and the expression levels of
target genes were normalized to that of the ß-actin gene, as
quantified using real-time qPCR asi n t e r n a lc o n t r o l s .N u c l e o t i d e
sequences of primers were as follows: IFI27 (sense) 59-
ctaggccacggaattaaccc-39, IFI27 (anti-sense) 59-gactgcagagtagc-
cacaag-39,I F I 4 4( s e n s e )5 9-gcatgtaacgcatcaggctt-39,I F I 4 4( a n t i -
sense) 59-ccacaccagcgtttaccaac-39,I S G 1 5( s e n s e )5 9-ctttgccagta-
caggagctt-39, ISG15 (anti-sense) 59-gcccttgttattcctcacca-39,
MX1 (sense) 59-aatcagcctgctgacattgg-39,M X 1( a n t i - s e n s e )5 9-
gtgatgagctcgctggtaag-39,O A S 1( s e n s e )5 9-gtgcgctcagcttcgtactg-
39,O A S 1( a n t i - s e n s e )5 9-actaggcggatgaggctctt-39,a n db-actin
(sense) 59-ccactggcatcgtgatggac-39, b-actin (anti-sense) 59-
tcattgccaatggtgatgacct-39.
Figure 4. The relationship between the expression level of genes which participate in IFN production (TLR7, MyD88, IRAK1, and
IRF7) in the liver of CH patients and IL28B genotype. (A) The relationship between IFN early response genes and clinical outcome is shown. A
summary table of the p-value is also presented. NS shows no significant difference. (B) The relationship between IFN early response genes and IL28
genotype is shown. The p-value is also presented.
doi:10.1371/journal.pone.0019799.g004
Table 7. Quality of NR-prediction by DLDA with IFN related
gene and IL28B polymorphism A.IFN+IL28B.
Predicted
NR nonNR Total
Diagnosed NR 7 2 9
nonNR 4 23 27
Total 11 25 36
doi:10.1371/journal.pone.0019799.t007
Table 8. Quality of NR-prediction by DLDA with IFN related
gene only.
Predicted
NR nonNR Total
Diagnosed NR 8 1 9
nonNR 5 22 27
Total 13 23 36
doi:10.1371/journal.pone.0019799.t008
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RNA was amplified and biotinylated using the MessageAmp-
Biotin Enhanced Kit (Ambion). DNA oligonucleotide probes were
synthesized onto a DNA microarray chip called Genopal
(Mitsubishi Rayon) in order to detect the 237 genes (200 genes
on Chip1 and 37 genes on Chip2) related to the innate immune
response. Hybridization was carried out overnight at 65uC using
Genopal in an hybridization buffer[0.12 M Tris-HCl/0.12 M
NaCl/0.05% Tween-20]. After hybridization, Genopal was
washed with hybridization buffer twice at 65uC for 20 min
followed by washing in 0.12 M Tris-HCl/0.12 M NaCl at 65uC
for 10 min. Genopal was then labeled with streptavidin-Cy5 (GE
Healthcare Bioscience, Tokyo, Japan). The fluorescent labeled-
Genopal was washed for 5 min four times with hybridization
buffer at RT and scanned at multiple exposure times ranging from
0 to 40s by DNA microarray reader (Yokogawa Electric Co,
Tokyo, Japan). Intensity values with the best exposure condition
for each spot were selected. The data presented here have been
deposited in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE20119: http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xlmbxyyumcwkeba
&acc=GSE20119. All data are MIAME compliant, and are also
registered with GEO.
Statistical analysis
To identify the genes that varied significantly among NR, R,
SVR and NL groups, one-way ANOVA and Turkey’s post hoc
tests were used to assess each of the 237 IFN related-genes on the
arrays. Benjamini-Hochberg correction for multiple hypotheses
testing was applied to all tests. P values ,0.05 were considered
statistically significant.
Method of predicting prognosis
The patients were randomly divided into two groups: one was
used as a TS and the other VS to calculate the prediction
discriminant. A prognosis signature (PS) was defined in terms of
the expression levels of the six genes that differed significantly
between NR and non-NR groups using post hoc analysis (IFI27,
IFI44, interferon-induced protein with tetratricopeptide repeats 3
(IFIT3), ISG15, MX1, OAS1). A prognosis predictor (PP) was
computed by applying a diagonal linear DLDA to the TS [33] and
then using it to predict the prognoses of the VS. The predicted and
actual prognoses of VS patients were compared to obtain the
following five measures of prognosis prediction performance:
accuracy (proportion of correctly predicted prognoses), sensitivity
(proportion of correctly predicted non-NR), specificity (proportion
of correctly predicted NR), PPV (proportion of actual non-NR
versus predicted non-NR) and NPV (proportion of actual NR
versus predicted NR).
Genetic Variation of IL28B Polymorphism
Genotypes rs8099917 was determined in 72 out of 87 patients
by Taqman SNP assays (Applied Biosystems) using a pre-designed
and functionally tested probe (ABI assay ID (C_11710096_10).
The experiment was carried out according to the manufacturer’s
instruction.
Supporting Information
Figure S1 Real-time qPCR validation of the five IFN
related genes. Each column represents the relative amount of
mRNAs normalized to expression level of b-actin. The data shown
are means+SD of three independent experiments. Asterisk was
indicated to the significant difference at p,0.05.
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